Positive and negative symptoms in chronic schizophrenics in a 12-months follow up under maintenance therapy with flupentixoi-decanoate;Positiv- und negativsymptomatik bei chronisch schizophrenen patienten unter erhaltungstherapie mit flupentixol-decanoat im 12-monats-verlauf

Fortschritte der Neurologie Psychiatrie

Volumn 66, Issue 10, 1998, Pages 442-449

  Pach, J ^a   Finkbeiner, T ^b   Glaser, T ^c   Haug, J ^d   Osterheider, M ^e   Tegeler, J ^f  

^a KLINIKEN ESSEN MITTE   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c BAYER AG   (Germany)

^d UNIVERSITY OF BASEL   (Switzerland)

^e UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^f HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; FLUPENTIXOL DECANOATE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG INDICATION; FEMALE; FOLLOW UP; HUMAN; INVOLUNTARY MOVEMENT; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEGATIVE SYNDROME; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SOCIAL PSYCHOLOGY; SYMPTOMATOLOGY;

EID: 0031766060     PISSN: 07204299     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-995283     Document Type: Article

References (64)

1. Andreasen, N. C.: Negative symptoms in schizophrenia: definition and reliability. Arch. Gen. Psychiatry 39 (1982) 784-788
2. Andreasen, N. C., S. A. Olsen: Negative vs. positive schizophrenia. Arch. Gen. Psychiatry 39 (1982) 789-794
3. Andreasen, N. C: The scale for assessment of negative symptoms (SANS). The University of Iowa, Iowa City 1983
4. Angrist, B., J. Rotrosen, S. Gershon: Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia. Psychopharmacology 72 (1980) 17-19
5. Bandelow, B., P. Müller, U. Frick et al.: Depressive syndromes in schizophrenic patients under neuroleptic therapy. ANI Study Group Berlin, Düsseldorf, Gottingen, Munich, Federal Republic of Germany. Eur. Arch. Psychiatry Clin. Neurosci. 241 (1992) 291-295
6. Bandelow, B., E. Rüther: Antipsychotische Behandlung, jüngste Weiterentwicklungen und pharmakologische Grundlagen. Psychopharmakotherapie 1 (1997) 6-17
7. Bersani, G., A. Grispini, S. Marini et al.: Neuroleptic-induced extrapyramidal side effects: clinical perspectives with ritanserin (R55667), a new selective 5-HT2 receptor blocking agent. Curr. Ther. Res. 40 (1986) 492-499
8. Bleich, A., S. L. Brown, R. Kahn, H. van Praag: The role of serotonin in schizophrenia. Schizophr. Bull. 14 (1988) 297-315
9. Bowen, J., S. Hirsch: Recruitment rates and factors affecting recruitment for a clinical trial of a putative anti-psychotic agent in the treatment of acute schizophrenia. Human Psychopharmacology 7 (1992) 337-341
10. Breier, A., R. W. Buchanan. D. Irish, W. T. Carpenter: Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns. Hosp-Community-Psychiatry 44 (1993) 1145-1149
11. Carman, J., J. Peuskens, A. Vangeneugden: Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. Intern. Clin. Psychopharmacology 10 (1995) 207-213
12. Carpenter, W. T., W. D. Heinrichs, L. D. Alphs: Treatment of negative symptoms. Schizophr. Bull. 11 (1985) 440-452
13. Chouinard, G., B. Jones, G. Remington, D. Bloom, D. Addington, G. W. Mac Ewan, A. Labelle, L. Beauclair, W. Arnott: A Canadian Multicenter Placebo-Controlled Study of Fixed Doses of Risperidone and Haloperidol in the Treatment of Chronic Schizophrenic Patients. J. Clin. Psychopharmacology 13 (1993) 25-40
14. Claus, A., J. Bollen, H. De Cuyper, M. Eneman, M. Malfroid, J. Peuskens, S. Heylen: Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr. Scand. 85 (1992) 295-305
15. Crow, T. J.: Molecular pathology of schizophrenia: more than one disease process? Br. Med. J. 280 (1980) 66-68
16. Crow, T. J.: The two-syndrome concept: Origins and current status. Schizophr. Bull. 9 (1985) 471-486
17. de Leon, J., G. M. Simpson, V. Peralta: Positive and negative symptoms in schizophrenia: where are the data? Biological Psychiatry 31 (1992) 431-434
18. Endicott, J., R. L. Spitzer, J. L. Fleiss: The Sickness Rating Scale: A Procedure for Measuring, Overcall Severity of Psychiatric. Disturbance Arch. Psychiatry 33 (1976) 766-771
19. Eufe, R., G. Wegener: Doppelblindvergleich von 2 Depotneuroleptika (Perphazin-önanthat und Flupentixol-Decanoat) bei chronischer Schizophrenie. Nervenarzt 50, 534-539
20. Ereshefsky, L, S. Lacombe: Pharmacological Profile of Risperidone. Can. J. Psychiatry Vol. 38, Suppl. 3 (1993)
21. Farde, L., A. L. Nordström, F. A. Wiesel, S. Pauli, C. Halldin, G. Sedvall: Positron Emission Tomographic Analysis of Central D1 and D2 Dopamine Receptor Occupancy in Patients Treated with classical Neuroleptics and Clozapine. Arch. Gen. Psychiatry 49 (1992) 538-544
22. Glazer, W. M., J. M. Kane: Depot neuroleptic therapy; an underutilized treatment option. J. Clin. Psychiatry 53 (1992) 426-433
23. Goldberg, S. C.: Negative and deficit symptoms in schizophrenia do respond to neuroleptics. Schizophr. Bull. 11 (1985) 453-456
24. Greil, W., W. Ludwig-Mayerhofer, B. Steller, A. Czernik, H. Giedke, B. Müller-Oerlinghausen, M. Osterheider, G. A. E. Rudolf, A. Sauer, J. Tegeler, and T. Wetterling: The recruitment process for a multicenter study on the long-term prophylactic treatment of affective disorders. J. Affect Disorders 28 (1993) 257-265
25. Gunby, B.: Clinical physiognomy of flupenthixol. Acta Psychiatr. Belg. 74 (1974) 441
26. Guy, W. (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM: 76-338, Washington, D. C., US Department of Health, Education, and Welfare (1976) 219-222
27. Hamilton, M., R. Card, G. G. Wallis, M. R. Mahmoud: A Comparative Trial of the Decanoates of Flupenthixol and Fluphenazine, Psychopharmacology 64 (1979) 225-229
28. Huang et al.: Untersuchung der therapeutischen Wirksamkeit von Flupenthixol bei der Behandlung von Patienten mit chronischer Schizophrenie vom Typ II. Zhonghua Shenjing Jingshen Kezazhi 24 (1995) 11-20
29. Johnson, A. W., N. A. Malik: A Double-Blind Comparison of Fluphenazine Decanoate and Flupenthixol Decanoate in the Treatment of acute Schizophrenia. Acta Psychiatr. Scand 51 (1975) 256-267
30. Johnstone, E. C., T. J. Crow, C. D. Frith, M. W. Carney, J. S. Price: Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet 1 (1979) 848-851
31. Kane, J., G. Honigfeld, J. Singer, H. Meltzer: Clozapine for the treatment-resistant schizophrenic, A double-blind comparison with chlorpromazme. Arch. Gen. Psychiatry 3 (1988) 573-581
32. Kapfhammer, H. P., E. Rüther: Depot-Neuroleptika. Springer Verlag, Berlin, Heidelberg 1988
33. Klosterkötter, J., M. Albers, E. M. Steinmeyer, A. Hensen, H. Saß: Positive oder negative Symptome, was ist brauchbarer für die Diagnose Schizophrenie? Nervenarzt 65 (1994) 444-453
34. Kong, D. S. G., S. H. Yeo: Flupenthixol decanoate and fluphenazine decanoate in chronic schizophrenia. Singapore. Med. J. 28 (1985) 551-555
35. Lewander, T.: Long-term studies of antipsychotic drugs in schizophrenia. Eur. Psychiatry 11 (1996) 127-134
36. Leysen, J., P. Janssen, A. Schotte, W. Luyten, A. Megens: Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors. Psychopharmacology 112 (1993) 40-54
37. Liebermann, J. A., A. Z. Saffermann, S. Pollack, S. Szymanski, C. Johns, A. Howard, M. Kronig, P. Bookstein, J. M. Kane: Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am. J. Psychiatry Dec. 151 (1994) 1744-1752
38. Lindenmayer, J.-P., S. Grochowski, L Mabugat: Clozapine effects on positive and negative symptoms: a six-month trial in treatment-refractory schizophrenics. Clin. Psychopharmacol. 14 (1994) 201-204
39. Lindenmayer, J.-P., S. Grochowski, R. B. Hyman: Five factor model of schizophrenia: replication across samples. Schizophrenia Research 14 (1995) 229-234
40. Lindström, E., B. Eriksson, A. Hellgren, L. von Knorring, G. Eberhard: Efficacy and Safety of Risperidone in the Long-Term Treatment of Patients with Schizophrenia. Clin. Therapeutics 17 (1995) 402-411
41. Marder, S. R., T. van Putten, J. Mintz, M. Lebell, J. McKenzie, G. Galtico: Maintenance therapy: New findings. In: Kane, J. M. (ed): Drug maintenance strategies in schizophrenia, APA, Washington 1984
42. Marder, S. R., R. C. Meibach: Risperidone in the Treatment of Schizophrenia. Am. J. Psychiatry 151 (1994) 825-835
43. Meltzer, H. Y., A. A. Sommers, D. J. Luccins: The effect of neuroleptics and other psychotropic drugs on negative symptoms in Schizophrenia. J. Clin. Pharmacology 6 (1986) 329-338
44. Miller, D. D., P. J. Perry, R. J. Cadoret, N. C. Andreasen: Clozapine's effect on negative symptoms in treatment-refractory schizophrenics. Compr. Psychiatry 35 (1994) 8-15
45. Möller, H.-J., H. Müller, R. L. Borison, N. R. Schooler, G. Chouinard: A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study. Eur. Arch. Psychiatry Clin. Neurosci. 245 (1994) 45-49
46. Möller, H.-J., H. M. van Praag, B. Aufdembrinke et al.: Negative symptoms in schizophrenia: considerations for clinical trials. Working group in negative symptoms in schizophrenia. Psychopharmacology 115 (1994) 221-228
47. Nyberg, S., Y. Nakashima, A.-L. Nordström, C. Halldin, L. Farde: Positron Emission Tomography of in-vivo Binding Characteristics of Atypical Antipsychotic Drugs, Review of D2 and 5HT2 Receptor Occupancy Studies and Clinical Response. Brit. J. Psychiatry 168 (1996) 40-44
48. Osterheider, M., T. Finkbeiner, J. Greger. H. J. Haug, J. Pach, R. Strobl, J. Tegeler, T. Reinertshofer: Differentielle Dosierungsstrategien in der Rezidivprophylaxe schizophrener Erkrankungen. Psychopharmakotherapie (1998), im Druck (1997)
49. Overall, J. E., D. R. Gorham: The Brief Psychiatric Rating Scale. Psychol. Rep. 10 (1962) 799-812
50. Pach, J., M. Osterheider, H. J. Haug, J. Greger, V. Schär, T. Finkbeiner, G. Berdling Budde: Neuroleptische Rezidiv-Prophylaxe schizophrener Störungen, Rekrutierungsphase und Selektionsprozeß. Psycho 23 (1997) 51-54
51. Peuskens, J., on behalf of the Risperidone Study Group: Risperidone in the Treatment of Patients with Chronic Schizophrenia: a Multi-National, Multi-Centre, Double-Blind, Parallel-Group Study versus Haloperidol. Brit. J. Psychiatry 166 (1995) 712-726
52. Philipp, M.: Risperidon zur ambulanten Behandlung chronisch schizophrener Patienten. Psychopharmakotherapie 1 (1997) 35 -40
53. Pietzker, A., W. Gaebel, W. Köpcke et al.: Intermittent vs. maintenance neuroleptic long-term treatment in schizophrenia - 2 year results of a German multicenter study. J. Psychiat. Res. 27 (1993) 321-339
54. Pinto, R., A. Bannerjee, N. Ghosh: A double-blind comparison of flupenthixol decanoate and fluphenazine decanoate in the treatment of chronic schizophrenia. Acta Psychiatr. Scand. 60 (1979) 313-322
55. Psychopharmakology Review Branch: Abnormal Involuntary Movements Scale. In: Bethesda, M. D.: Early Clinical Drug Evaluation Unit Intercom. National Institute for Mental Health, 1975
56. Quinlan, D. M., D. Schuldberg, H. Morgenstern, W. Glazer: Positive and Negative Symptom Course in Chronic Community-Based Patients. A Two-Year Prospective Study. Brit. J. Psychiatry 166 (1995) 634-641
57. Serafetinides, E. A., D. Willis, M. D. Clark: Haloperidol, clopenthixol and chlorpromazine in chronic schizophrenia. J. Nerv. Ment. Dis. 155 (1972) 366-369
58. Serban, G., S. Siegal, M. Gaffney: Response of negative symptoms of schizophrenia to neuroleptic treatment. J. Clin. Psychiatry 53 (1992) 229-234
59. Sieberns, S.: Erfahrungen mit dem Depot-Neuroleptikum Flupenthixol - eine Übersicht. Pharmakopsychiatry 11 (1978) 186-198
60. Strauss, J. S., W. T. Carpenter: The prediction of outcome in schizophrenia. Arch. Gen. Psychiatry 27 (1972) 739-746
61. Szymanski, S. R., T. D. Cannon, F. Gallacher, R. J. Erwin, R. E. Gur: Course of treatment response in first-episode and chronic schizophrenia. Am. J. Psychiatry 153 (1996) 519-525
62. Tollefson, G. D., C. M. Beasley, P. V. Tran, J. S. Street, J. A. Krueger, R. N. Tamura, K. A. Graffeio, M. E. Thieme: Olanzapine versus Haloperidol in the Treatment of Schizophrenia and Schizoaffective and Schizophreniform Disorders: Results of an International Collaborative Trial. Am. J. Psychiatry 154 (1997) 457-465
63. Wyatt, R. J.: Neuroleptics and the Natural Course of Schizophrenia. Schizophr. Bull. 17 (1991) 325-351
64. Zimbroff, D. L., J. M. Kane, C. A. Tamminga, D. G. Daniel, R. J. Mack, P. J. Wozniak, T. B. Sebree, B. A. Wallin, K. B. Kashkin and the Sertindole Study Group: Controlled, Dose-Response Study of Sertindole and Haloperidol in the Treatment of Schizophrenia. Am. J. Psychiatry 154 (1997) 782-791